[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550705":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":49,"collaborators":19,"id":51,"slug":19,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":19,"enrollmentInfo":60,"targetDuration":19,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":35,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Centre Henri Becquerel","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dynamic and static acquisition","EXPERIMENTAL","Dynamic and static PET acquisitions with 18F-FDG and 68Ga-PSMA will be performed with a minimum of 24 hours and a maximum of 15 days between the two",[13],"Other: Parametric acquisition",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Parametric acquisition","Parametric acquisition for 18F-FDG PET\u002FCT and 68GA-PSMA PET\u002FCT with 24 h at 15 days of interval",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Pierre Decazes, MD,PhD","STUDY_DIRECTOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","+3276673059","pierre.decazes@chb.unicancer.fr",{"name":30,"role":26,"phone":31,"phoneExt":19,"email":32},"Doriane Richard, PhD","+3232082985","doriane.richard@chb-unicancer.fr",[34],{"facility":5,"status":35,"city":36,"state":19,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Rouen","76000","France",{"type":40,"coordinates":41},"Point",[42,43],1.09932,49.44313,{"lat":43,"lon":42},[46],{"name":47,"role":26,"phone":48,"phoneExt":19,"email":28},"Pierre Decazes, Md","+3376673059",{"type":50,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100550705",false,"NCT06450548","Dynamic 68Ga-PSMA and 18F-FDG PET\u002FCT Analysis Prior to 177Lu-PSMA","Dynamic 68Ga-PSMA and 18F-FDG PET\u002FCT Analysis of Metastatic Prostatic Adenocarcinomas Prior to 177Lu-PSMA Treatment","PYPET","Inclusion Criteria:\n\n* Signed informed consent.\n* Progressive metastatic castration-resistant prostate adenocarcinoma, which has been treated with taxane chemotherapy and at least one anti-androgen hormone therapy.\n* Evaluated by 18F-FDG and 68Ga-PSMA PET\u002FCT prior to potential treatment with 177Lu-PSMA.\n* Affiliated with or beneficiary of a social protection scheme.\n* WHO stage 0 or 1.\n\nExclusion Criteria:\n\n* Patients unable to understand the study for any reason or comply with the trial requirements (due to language barriers, psychological issues, geographical constraints, etc.).\n* Patients unable to undergo the examinations and\u002For maintain a prolonged lying position (due to back pain, etc.).","MALE","18 Years",{"count":61,"type":62},60,"ESTIMATED","INTERVENTIONAL",[65],"NA","Prostate cancer is a significant health issue, representing 21.8% of male cancer cases in France with over 449,000 new cases in 2018. It's the cause of 10% of cancer deaths in Europe.\n\nThe PSMA is a target for mCRPC treatment, with therapies like 177Lu-PSMA-617 delivering radiation to cancer cells. The Vision study showed that 177Lu-PSMA-617, combined with standard care, improved survival rates significantly compared to standard care alone.The French ANSM authorized 177Lu-PSMA-617 for mCRPC under certain conditions. Patients must have histologically confirmed mCRPC, be progressive despite treatment, and have PSMA-positive imaging.\n\nImaging assessments include PSMA PET\u002FCT and 18F-FDG PET\u002FCT to identify FDG-positive and PSMA-negative sites, which are associated with a poorer prognosis.\n\nParametric analysis using dynamic PET could improve lesion characterization, aiding in treatment decisions. This is the focus of the PyPET study.\n\nThe main objective focuses on a comparative analysis of data from dynamic parametric analysis (metabolic influx rate Ki, volume of distribution Vd) and static analysis (standard at 1 hour) using 18F-FDG and 68Ga-PSMA PET\u002FCT for diagnosing metastases, especially in the liver, lymph nodes, and bones. It aims to assess the effectiveness of these imaging techniques in accurately identifying metastatic sites.",[68],"Prostate Cancer Metastatic",[70,71,72],"prostate cancer","68GA-PSMA","parametric acquisition","2025-12-29",{"date":75,"type":76},"2026-01-02","ACTUAL",{"date":78,"type":76},"2025-03-05",{"date":80,"type":62},"2028-03-05",{"name":5,"class":6},1]